Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eli Lilly
(NY:
LLY
)
819.93
-0.17 (-0.02%)
Streaming Delayed Price
Updated: 2:52 PM EDT, Oct 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
October 15, 2025
Novo Nordisk’s $4.7B Akero deal boosts its metabolic health pipeline, targeting Eli Lilly’s lead in obesity and liver disease treatments
Via
MarketBeat
Topics
World Trade
Chesapeake Asset Management Begins Investing in Ryder System. Is the Stock a Buy?
October 15, 2025
Via
The Motley Fool
Topics
Economy
Regulatory Compliance
Eli Lilly's Oral Weight Loss Drug Shows Superiority Over Two Approved Drugs
October 15, 2025
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 diabetes.
Via
Benzinga
Eli Lilly Stock: Elevated Momentum, Strong Analyst Backing, Near-Term Earnings Focus
October 15, 2025
Eli Lilly's stock shows robust momentum and strong analyst support, driven by solid fundamentals and positive market sentiment, while upcoming earnings releases remain a focal point for investors.
Via
Talk Markets
Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials
October 15, 2025
Via
Stocktwits
Smart Money Is Betting Big In LLY Options
October 10, 2025
Via
Benzinga
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
October 15, 2025
The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.
Via
The Motley Fool
New to Investing? These Are 3 Solid Blue Chip Stocks You Can Build Your Portfolio Around
October 15, 2025
Regardless of your investing knowledge or experience, you can't go wrong with these three behemoths in your portfolio.
Via
The Motley Fool
Topics
Artificial Intelligence
1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today
October 14, 2025
Despite the company's run in recent years, it's not too late to buy.
Via
The Motley Fool
Independence Bank of Kentucky Buys Another $3.1 Million Eli Lilly (NYSE: LLY) Shares
October 14, 2025
Via
The Motley Fool
Topics
ETFs
Regulatory Compliance
3 Healthcare Companies Insiders Are Buying
October 14, 2025
Insiders are buying these three healthcare companies that have catalysts to drive their share prices higher in the upcoming years.
Via
MarketBeat
Topics
Initial Public Offering
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
October 13, 2025
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.
Via
Stocktwits
Jim Cramer Declares Wall Street Divided: Three Distinct Markets Emerge
October 13, 2025
Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Recent Filing Shows That Sen. John Boozman Bought Over $49K Worth of iShares 7-10 Year Treasury Bond ETF Stock
October 13, 2025
Via
Benzinga
Topics
ETFs
Down 44%, Should You Buy the Dip on Viking Therapeutics?
October 13, 2025
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Via
The Motley Fool
Healthcare Opportunities And Risks Collide For Direxion's Eli Lilly-Focused ELIL, ELIS ETFs
October 13, 2025
Via
Benzinga
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
October 13, 2025
Is it too late to get on the bandwagon?
Via
The Motley Fool
The Smartest Growth Stock to Buy With $100 Right Now
October 13, 2025
This beaten-down drugmaker is well positioned to turn things around.
Via
The Motley Fool
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
October 13, 2025
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via
The Motley Fool
Topics
ETFs
Government
World Trade
Should You Buy Novo Nordisk Right Now?
October 12, 2025
The fallen pharma giant could make a big comeback in 2026.
Via
The Motley Fool
Should Investors Buy Eli Lilly Stock?
October 11, 2025
Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies.
Via
The Motley Fool
MarketBeat Week in Review – 10/06 - 10/10
October 11, 2025
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data
Via
MarketBeat
Topics
Economy
Why Hims & Hers Health (HIMS) Stock Is Nosediving
October 10, 2025
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue...
Via
StockStory
Topics
World Trade
Bill Gates And PAHO Push To Make Weight-Loss Drugs Accessible In Low-Income Nations
October 10, 2025
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.
Via
Benzinga
1 Vanguard ETF to Invest In That Can Turn $500 Monthly Into $800,000
October 10, 2025
This ETF has shown market-beating potential since its inception.
Via
The Motley Fool
Topics
ETFs
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now
October 10, 2025
Ongoing developments make these companies look attractive.
Via
The Motley Fool
Topics
Economy
World Trade
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
October 09, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions
October 09, 2025
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in...
Via
MarketMinute
Direxion's QQQU, QQQD ETFs Foster A Diversified Approach To Magnificent 7 Speculation
October 09, 2025
Via
Benzinga
Topics
ETFs
5 Healthcare Plays Powering the Sector’s Big Comeback
October 09, 2025
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.